Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug Alexandre Rafael de Mello Schier, Natalia Pinho de Oliveira Ribeiro, Adriana Cardoso de Oliveira e Silva, Jaime Eduardo Cecilio Hallak, José Alexandre S. Crippa, Antonio E. Nardi, Antonio Waldo Zuardi Revista Brasileira de Psiquiatria, 2012, 34 (Supl1), S104-S117 1516-4446 - ©2012 Elsevier Editora Ltda. All rights reserved. Abstract Objectives : To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. Method : The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI [...]
Lire la suiteFluorinated Cannabidiol Derivatives : Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects Aviva Breuer, Christeene G. Haj, Manoela V. Fogaça, Felipe V. Gomes, Nicole, Rodrigues Silva, João Francisco Pedrazzi, Elaine A. Del Bel, Jaime C. Hallak, José, A. Crippa, Antonio W. Zuardi, Raphael Mechoulam, Francisco S. Guimarães PLOS ONE, Research Article, 2016 | DOI:10.1371/journal.pone.0158779 July 14, 2016 Abstract Cannabidiol (CBD) is a major Cannabis sativa constituent, which does not cause the typical marijuana psychoactivity. However, it has been shown to be active in a numerous pharmacological assays, including mice tests for anxiety, obsessive-compulsive disorder, depression and schizophrenia. In human trials [...]
Lire la suiteCannabidiol as a Potential Treatment for Anxiety Disorders. Blessing E.M.; Steenkamp M.M.; Manzanares J.; Marmar C.R. Neurotherapeutics, 2015, 12, 4, 825-36 doi:10.1007/s13311-015-0387-1 (ISSN: 1878-7479) Abstract : Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD's potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, [...]
Lire la suiteCannabidiol in Anxiety and Sleep : A Large Case Series Scott Shannon, Nicole Lewis, Heather Lee, Shannon Hughes, The Permanente Journal, 2019, 23, 18-041 doi.org/10.7812/TPP/18-041 ABSTRACT Context : Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a “high.” A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical [...]
Lire la suitePharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy James W. Wheless, · Dennis Dlugos, · Ian Miller, · D. Alexander Oh, · Neha Parikh, · Steven Phillips, · J. Ben Renfroe, · Colin M. Roberts, · Isra Saeed, · Steven P. Sparagana, · Jin Yu, · Maria Roberta Cilio, on behalf of the INS011-14-029 Study Investigators CNS Drugs, 2019 https://doi.org/10.1007/s40263-019-00624-4 Abstract Background : Prior studies have evaluated the use of various constituents of cannabis for their anti-seizure effects. Specifically, cannabidiol, a non-psychoactive component of cannabis, has been investigated for treatment-resistant epilepsy, but more information is needed particularly on [...]
Lire la suiteCannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Arkell T.R., Lintzeris N., Kevin R.C., Ramaekers J.G., Vandrey R., Irwin C., Haber P.S., McGregor I.S. Psychopharmacology (Berlin), 2019 DOI : 10.1007/s00213-019-05246-8 PMID : 31044290 Abstract BACKGROUND : The main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), can impair driving performance. Cannabidiol (CBD), a non-intoxicating cannabis component, is thought to mitigate certain adverse effects of THC. It is possible then that cannabis containing equivalent CBD and THC will differentially affect driving and cognition relative to THC-dominant cannabis. AIMS : The present study investigated and compared the effects of THC-dominant and [...]
Lire la suiteDescriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans Marco Colizzi, NathalieWeltens, Philip McGuire, Lukas Van Oudenhove and Sagnik Bhattacharyya Brain Sciences, 2019, 9, 93 doi : 10.3390/brainsci9040093 Abstract : Background : Cannabis use can increase the risk of psychosis, and the acute administration of its key psychoactive ingredient, delta-9-tetrahydrocannabinol (D9-THC), can induce transient psychotomimetic symptoms. Methods : A double-blind, randomized, placebo-controlled crossover design was used to investigate the symptomatic effects of acute intravenous administration of D9-THC (1.19 mg/2 mL) in 16 healthy participants (seven males) with modest previous cannabis exposure. Results : In the 20 min following acute D9-THC administration, symptomatic effects of [...]
Lire la suiteEffects of delta-9-tetrahydrocannabinol on evaluation of emotional images Michael E Ballard, Gillinder Bedi, and Harriet de Wit Journal of Psychopharmacology, 2012, 26, 10, 1289–1298. doi:10.1177/0269881112446530. Abstract There is growing evidence that drugs of abuse alter processing of emotional information in ways that could be attractive to users. Our recent report that Δ9-tetrahydrocannabinol (THC) diminishes amygdalar activation in response to threat-related faces suggests that THC may modify evaluation of emotionally-salient, particularly negative or threatening, stimuli. In this study, we examined the effects of acute THC on evaluation of emotional images. Healthy volunteers received two doses of THC (7.5 and 15 mg; p.o.) and placebo across separate [...]
Lire la suiteAcute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users Chandni Hindocha, Tom P. Freeman, Grainne Schafer, Chelsea Gardener, Ravi K. Das, Celia J.A. Morgan and H. Valerie Curran Eur Neuropsychopharmacology, 2015, 25, 3, 325–334. doi:10.1016/j.euroneuro.2014.11.014 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398332/?report=printable Abstract Acute administration of the primary psychoactive constituent of cannabis, Δ-9-tetrahydrocannabinol (THC), impairs human facial affect recognition, implicating the endocannabinoid system in emotional processing. Another main constituent of cannabis, cannabidiol (CBD), has seemingly opposite functional effects on the brain. This study aimed to determine the effects of THC and CBD, both alone and in combination on emotional facial affect [...]
Lire la suiteCannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Amir Englund, Paul D Morrison, Judith Nottage, Dominic Hague, Fergus Kane1, Stefania Bonaccorso1, James M Stone, Avi Reichenberg, Rudolf Brenneisen, David Holt, Amanda Feilding, Lucy Walker, Robin M Murray and Shitij Kapur Journal of Psychopharmacology, 2012 Doi : 10.1177/0269881112460109 Abstract Community-based studies suggest that cannabis products that are high in Δ9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited [...]
Lire la suite